TNON vs SIBN vs ATEC vs XTNT vs GMED

For growth investors, Xtant Medical Holdings, Inc.

(XTNT) is the stronger pick with 28. 4% revenue growth year-over-year, versus 11. 9% for Tenon Medical, Inc. (TNON). Globus Medical, Inc. (GMED) offers the better valuation at 21. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate SI-BONE, Inc. (SIBN) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Globus Medical, Inc.

is actually cheaper at 19. 0x.

Over the past 5 years, Globus Medical, Inc.

(GMED) delivered a total return of +16. 1%, compared to -100. 0% for Tenon Medical, Inc. (TNON). Over 10 years, the gap is even starker: GMED returned +264. 4% versus TNON's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.

(XTNT) is the lower-risk stock at 0. 69β versus Globus Medical, Inc. 's 1. 29β — meaning GMED is approximately 87% more volatile than XTNT relative to the S&P 500. On balance sheet safety, SI-BONE, Inc. (SIBN) carries a lower debt/equity ratio of 1% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xtant Medical Holdings, Inc.

(XTNT) is pulling ahead at 28. 4% versus 11. 9% for Tenon Medical, Inc. (TNON). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to 15. 0% for Alphatec Holdings, Inc.. Over a 3-year CAGR, TNON leads at 173. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Globus Medical, Inc.

(GMED) is the more profitable company, earning 18. 3% net margin versus -417. 2% for Tenon Medical, Inc. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMED leads at 16. 3% versus -420. 1% for TNON. At the gross margin level — before operating expenses — SIBN leads at 79. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Globus Medical, Inc.

(GMED) trades at 19. 0x forward P/E versus 27. 1x for Alphatec Holdings, Inc. — 8. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATEC: 222. 6% to $25. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Xtant Medical Holdings, Inc.

(XTNT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69)). Both have compounded well over 10 years (XTNT: -97. 8%, TNON: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TNON is a small-cap quality compounder stock; SIBN is a small-cap high-growth stock; ATEC is a small-cap high-growth stock; XTNT is a small-cap high-growth stock; GMED is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.